Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):1907–1912. doi: 10.1128/aac.39.9.1907

Use of amphotericin B with azole antifungal drugs: what are we doing?

A M Sugar 1
PMCID: PMC162855  PMID: 8540690

Full Text

The Full Text of this article is available as a PDF (169.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert M. M., Graybill J. R., Rinaldi M. G. Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination. Antimicrob Agents Chemother. 1991 Sep;35(9):1721–1725. doi: 10.1128/aac.35.9.1721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anaissie E. J., Karyotakis N. C., Hachem R., Dignani M. C., Rex J. H., Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis. 1994 Aug;170(2):384–389. doi: 10.1093/infdis/170.2.384. [DOI] [PubMed] [Google Scholar]
  3. Anséhn S., Nilsson L. Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP. Antimicrob Agents Chemother. 1984 Jul;26(1):22–25. doi: 10.1128/aac.26.1.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Atkinson B. A., Bocanegra R., Colombo A. L., Graybill J. R. Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B. Antimicrob Agents Chemother. 1994 Jul;38(7):1604–1607. doi: 10.1128/aac.38.7.1604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bennett J. E., Dismukes W. E., Duma R. J., Medoff G., Sande M. A., Gallis H., Leonard J., Fields B. T., Bradshaw M., Haywood H. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. doi: 10.1056/NEJM197907193010303. [DOI] [PubMed] [Google Scholar]
  6. Brajtburg J., Kobayashi D., Medoff G., Kobayashi G. S. Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis. 1982 Aug;146(2):138–146. doi: 10.1093/infdis/146.2.138. [DOI] [PubMed] [Google Scholar]
  7. Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Como J. A., Dismukes W. E. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994 Jan 27;330(4):263–272. doi: 10.1056/NEJM199401273300407. [DOI] [PubMed] [Google Scholar]
  9. Cosgrove R. F., Beezer A. E., Miles R. J. In vitro studies of amphotericin B in combination with the imidazole antifungal compounds clotrimazole and miconazole. J Infect Dis. 1978 Nov;138(5):681–685. [PubMed] [Google Scholar]
  10. Fromtling R. A. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988 Apr;1(2):187–217. doi: 10.1128/cmr.1.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. George D., Kordick D., Miniter P., Patterson T. F., Andriole V. T. Combination therapy in experimental invasive aspergillosis. J Infect Dis. 1993 Sep;168(3):692–698. doi: 10.1093/infdis/168.3.692. [DOI] [PubMed] [Google Scholar]
  12. Ghannoum M. A., Spellberg B. J., Ibrahim A. S., Ritchie J. A., Currie B., Spitzer E. D., Edwards J. E., Jr, Casadevall A. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother. 1994 Sep;38(9):2029–2033. doi: 10.1128/aac.38.9.2029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Greenwood D. In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis. 1981 Oct;144(4):380–385. doi: 10.1093/infdis/144.4.380. [DOI] [PubMed] [Google Scholar]
  14. Martin E., Maier F., Bhakdi S. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother. 1994 Jun;38(6):1331–1338. doi: 10.1128/aac.38.6.1331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meyer R. D. Current role of therapy with amphotericin B. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S154–S160. doi: 10.1093/clinids/14.supplement_1.s154. [DOI] [PubMed] [Google Scholar]
  16. Petrou M. A., Rogers T. R. Interactions in vitro between polyenes and imidazoles against yeasts. J Antimicrob Chemother. 1991 Apr;27(4):491–506. doi: 10.1093/jac/27.4.491. [DOI] [PubMed] [Google Scholar]
  17. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy. 1987;33(5):381–395. doi: 10.1159/000238524. [DOI] [PubMed] [Google Scholar]
  18. Powderly W. G., Saag M. S., Cloud G. A., Robinson P., Meyer R. D., Jacobson J. M., Graybill J. R., Sugar A. M., McAuliffe V. J., Follansbee S. E. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992 Mar 19;326(12):793–798. doi: 10.1056/NEJM199203193261203. [DOI] [PubMed] [Google Scholar]
  19. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994 Feb;18(2):240–242. doi: 10.1093/clinids/18.2.240. [DOI] [PubMed] [Google Scholar]
  20. Reitz M., Jaeger K. H. Effects of 1-(halogenalkoxy)alkyl-5-fluorouracil derivatives on cell growth, cell volume and nucleus size of mouse lymphoma cells. Chemotherapy. 1992;38(1):57–65. doi: 10.1159/000238942. [DOI] [PubMed] [Google Scholar]
  21. Rex J. H., Bennett J. E., Sugar A. M., Pappas P. G., van der Horst C. M., Edwards J. E., Washburn R. G., Scheld W. M., Karchmer A. W., Dine A. P. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994 Nov 17;331(20):1325–1330. doi: 10.1056/NEJM199411173312001. [DOI] [PubMed] [Google Scholar]
  22. Rex J. H., Pfaller M. A., Barry A. L., Nelson P. W., Webb C. D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 1995 Jan;39(1):40–44. doi: 10.1128/aac.39.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rex J. H., Pfaller M. A., Rinaldi M. G., Polak A., Galgiani J. N. Antifungal susceptibility testing. Clin Microbiol Rev. 1993 Oct;6(4):367–381. doi: 10.1128/cmr.6.4.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sangeorzan J. A., Bradley S. F., He X., Zarins L. T., Ridenour G. L., Tiballi R. N., Kauffman C. A. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994 Oct;97(4):339–346. doi: 10.1016/0002-9343(94)90300-x. [DOI] [PubMed] [Google Scholar]
  25. Schaffner A., Böhler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses. 1993 Nov-Dec;36(11-12):421–424. doi: 10.1111/j.1439-0507.1993.tb00732.x. [DOI] [PubMed] [Google Scholar]
  26. Schaffner A., Frick P. G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985 May;151(5):902–910. doi: 10.1093/infdis/151.5.902. [DOI] [PubMed] [Google Scholar]
  27. Schmitt H. J., Bernard E. M., Edwards F. F., Armstrong D. Combination therapy in a model of pulmonary aspergillosis. Mycoses. 1991 Jul-Aug;34(7-8):281–285. doi: 10.1111/j.1439-0507.1991.tb00660.x. [DOI] [PubMed] [Google Scholar]
  28. Sharkey-Mathis P. K., Velez J., Fetchick R., Graybill J. R. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr. 1993 Jul;6(7):809–819. [PubMed] [Google Scholar]
  29. Shigematsu M. L., Uno J., Arai T. Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):919–924. doi: 10.1128/aac.21.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis. 1983 Jun;147(6):1070–1077. doi: 10.1093/infdis/147.6.1070. [DOI] [PubMed] [Google Scholar]
  31. Sugar A. M., Hitchcock C. A., Troke P. F., Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother. 1995 Mar;39(3):598–601. doi: 10.1128/AAC.39.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sugar A. M. Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination. Antimicrob Agents Chemother. 1991 Aug;35(8):1669–1671. doi: 10.1128/aac.35.8.1669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sugar A. M., Salibian M., Goldani L. Z. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob Agents Chemother. 1994 Feb;38(2):371–373. doi: 10.1128/aac.38.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Surarit R., Shepherd M. G. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J Med Vet Mycol. 1987 Dec;25(6):403–413. doi: 10.1080/02681218780000491. [DOI] [PubMed] [Google Scholar]
  35. Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 Dec;12(12):911–915. doi: 10.1007/BF01992164. [DOI] [PubMed] [Google Scholar]
  36. Uno J., Shigematsu M. L., Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):912–918. doi: 10.1128/aac.21.6.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Van den Bossche H., Ruysschaert J. M., Defrise-Quertain F., Willemsens G., Cornelissen F., Marichal P., Cools W., Van Cutsem J. The interaction of miconazole and ketoconazole with lipids. Biochem Pharmacol. 1982 Aug 15;31(16):2609–2617. doi: 10.1016/0006-2952(82)90707-9. [DOI] [PubMed] [Google Scholar]
  38. Vuffray A., Durussel C., Boerlin P., Boerlin-Petzold F., Bille J., Glauser M. P., Chave J. P. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS. 1994 May;8(5):708–709. doi: 10.1097/00002030-199405000-00023. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES